1.Lowy, DRD (2016) HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. The Journal of Clinical Investigation 126, 5–11.
2.Joura, EA et al. (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine 372, 711–723.
3.Wang, CJ and Palefsky, JM (2015) Human papillomavirus (HPV) infections and the importance of HPV vaccination. Current Epidemiology Reports 2, 101–109.
4.Kessels, SJM et al. (2012) Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 30, 3546–3556.
5.Lopalco, P (2016) Spotlight on the 9-valent HPV vaccine. Drug Design, Development and Therapy 11, 35–44.
6.Pomfret, TC, Gagnon, JM Jr. and Gilchrist, AT (2011) Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. Journal of Clinical Pharmacy and Therapeutics 36, 1–9.
7.Bonanni, P et al. (2011) An overview on the implementation of HPV vaccination in Europe. Human Vaccines 7, 128–135.
8.Paavonen, J et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet 374, 301–314.
9.Gattoc, L, Nair, N and Ault, K (2013) Human papillomavirus vaccination. Obstetrics and Gynecology Clinics of North America 40, 177–197.
10.Markowitz, LE et al. (2007) Quadrivalent human papillomavirus vaccine. Morbidity and Mortality Weekly Report 56, 1–24.
11.Skinner, SR and Cooper Robbins, SC (2010) Voluntary school-based human papillomavirus vaccination: an efficient and acceptable model for achieving high vaccine coverage in adolescents. Journal of Adolescent Health 47, 215–218.
12.Dorleans, F et al. (2010) The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 15, 10–17.
13.Szarewski, A (2010) HPV vaccine: Cervarix. Expert Opinion on Biological Therapy 10, 477–487.
14.Arbyn, M et al. (2018) Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD009069. DOI: 10.1002/14651858.CD009069.pub3.
15.Higgins, J and Green, S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
16.Moher, D et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6, 1–6.
17.Higgins, J, Altman, D and Gotzshe, P (2011) The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ British Medical Journal 343, d5928.
18. R Core Team (2017) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
19.Kim, YJ et al. (2010) Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10–14 years. Journal of Korean Medical Science 25, 1197–1204.
20.Harper, DM et al. (2006) Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. The Lancet 367, 1247–1255.
21.Kang, S et al. (2008) Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. International Journal of Gynecological Cancer 18, 1013–1019.
22.Reisinger, KS et al. (2007) Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatric Infectious Disease Journal 26, 201–209.
23.Levin, MJ et al. (2010) Safety and immunogenicity of a quadrivalent human papillomaviru (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. Journal of Acquired Immune Deficiency Syndromes 55, 197–204.
24.Giuliano, A et al. (2011) Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males. New England Journal of Medicine 364, 401–411.
25.Muñoz, N et al. (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet 373, 1949–1957.
26.Castellsagué, X et al. (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. British Journal of Cancer 105, 28–37.
27.Villa, LL et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer 95, 1459–1466.
28.Villa, LL et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology 6, 271–278.
29.Rivera Medina, DM et al. (2010) Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Journal of Adolescent Health 46, 414–421.
30.Vesikari, T et al. (2015) A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatric Infectious Disease Journal 34, 992–998.
31.Konno, R et al. (2010) Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years. International Journal of Gynecological Cancer 20, 847–855.
32.Lehtinen, M et al. (2016) Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: interim analysis of a large community-randomized controlled trial. Human Vaccines and Immunotherapeutics 12, 3177–3185.
33.Moreira, ED et al. (2011) Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Human Vaccines 7, 768–775.
34.Salif Sow, P et al. (2013) Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-seronegative African girls and young women. Journal of Infectious Diseases 207, 1753–1763.
35.Wheeler, CM et al. (2008) Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26, 686–696.
36.Herrero, R et al. (2013) Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8, e68329.
37.Beachler, DC et al. (2016) Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. Journal of the National Cancer Institute 108, djv302.
38.Hildesheim, A et al. (2014) Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32, 5087–5097.
39.Herrero, R et al. (2011) Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery 1, 408–419.
40.Lazcano-Ponce, E et al. (2009) Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. Archives of Medical Research 40, 514–524.
41.Kim, SC et al. (2011) Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15–25 years old healthy Korean women. Journal of Gynecologic Oncology 22, 67–75.
42.Mugo, N et al. (2015) Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Human Vaccines and Immunotherapeutics 11, 1323–1330.
43.Wheeler, CM et al. (2016) Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. The Lancet Infectious Diseases 16, 1154–1168.
44.Zhu, F-C et al. (2014) Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. International Journal of Cancer 135, 2612–2622.
45.Olsson, S-E et al. (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931–4939.
46.Apter, D et al. (2015) Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clinical and Vaccine Immunology 22, 361–373.
47.Szarewski, A et al. (2012) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. International Journal of Cancer 131, 106–116.
48.Palmroth, J et al. (2012) Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. International Journal of Cancer 131, 2832–2838.
49.Toft, L et al. (2014) Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. Journal of Infectious Diseases 209, 1165–1173.
50.Einstein, MH et al. (2014) Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: end-of-study analysis of a phase III randomized trial. Human Vaccines and Immunotherapeutics 10, 3435–3445.
51.Schmeink, CE et al. (2011) Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine 29, 9276–9283.
52.Konno, R et al. (2014) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines & Immunotherapeutics 10, 1781–1794.
53.Naud, P et al. (2014) Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine final analysis of a long-term follow-up study up to 9.4 years. Human Vaccines & Immunotherapeutics 10, 2147–2162.
54.Lim, BK et al. (2014) Immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine in Malaysian women aged 18–35 years: a randomized controlled trial. The Medical Journal of Malaysia 69, 2–8.
55.Pagliusi, SR et al. (2006) Chapter 23: international standard reagents for harmonization of HPV serology and DNA assays – an update. Vaccine 24, S193–S200.
56.Dessy, FJ et al. (2008) Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Human Vaccines 4, 425–434.
57.Carter, JJ et al. (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. The Journal of Infectious Diseases 181, 1911–1919.
58.Mariani, L and Venuti, A (2010) HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. Journal of Translational Medicine 8, 105.
59.Wang, JW and Roden, RB (2013) Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Review of Vaccines 12, 129–141.
60.Stanley, M (2006) Prophylactic HPV vaccines. Journal of Clinical Pathology 60, 961–965.
61.Einstein, MH et al. (2009) Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Human Vaccines 5, 705–719.